Fevipiprant: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

29 April 2024

28 April 2024

12 December 2023

17 August 2023

9 May 2023

24 January 2023

11 July 2021

5 December 2020

20 September 2020

22 June 2020

26 April 2020

17 April 2020

15 April 2020

16 December 2019

  • curprev 07:3307:33, 16 December 2019Michael Frind talk contribs 4,106 bytes +622 Added additional, referenced information from just-released Reuters News article (Dec 15-16/2019). Basel-based Novartis has decided to give up on Fevipiprant, given how this drug has now failed two more important clinicial trials (this time for moderate-to-severe-asthma patients). This organohalogen drug is thus being jettisoned from this company's development program. undo

16 August 2019

12 August 2019

19 May 2018

13 June 2017

22 May 2017

3 January 2017

17 December 2016

13 December 2016

14 November 2016

27 August 2016

7 August 2016

6 August 2016